Optic Neuropathy (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy – Drugs In Development, 2021, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Antoxis Ltd

Astellas Pharma Inc

Biozeus Pharmaceutical SA

jCyte Inc

Neurizon Pharma GBR

PharmatrophiX Inc

Quark Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuropathy - Overview

Optic Neuropathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuropathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuropathy - Companies Involved in Therapeutics Development

Antoxis Ltd

Astellas Pharma Inc

Biozeus Pharmaceutical SA

jCyte Inc

Neurizon Pharma GBR

PharmatrophiX Inc

Quark Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Optic Neuropathy - Drug Profiles

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BZ-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Glaucoma and Optic Neuropathies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSIC-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELN-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fab-3H4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22A4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Optic Neuropathy and Retinal Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Glaucoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuropathy - Dormant Projects

Optic Neuropathy - Discontinued Products

Optic Neuropathy - Product Development Milestones

Featured News & Press Releases

Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting

Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007

Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’

Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007

Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant

Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications

Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION

Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Optic Neuropathy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Optic Neuropathy – Pipeline by Antoxis Ltd, 2021

Optic Neuropathy – Pipeline by Astellas Pharma Inc, 2021

Optic Neuropathy – Pipeline by Biozeus Pharmaceutical SA, 2021

Optic Neuropathy – Pipeline by jCyte Inc, 2021

Optic Neuropathy – Pipeline by Neurizon Pharma GBR, 2021

Optic Neuropathy – Pipeline by PharmatrophiX Inc, 2021

Optic Neuropathy – Pipeline by Quark Pharmaceuticals Inc, 2021

Optic Neuropathy – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Optic Neuropathy – Dormant Projects, 2021

Optic Neuropathy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Optic Neuropathy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports